Within 3 Opinion leaders – both traditional KOLs and DOLs – have a tremendous influence on HCPs
  • April 15, 2022
  • 0 Comment
Read More
Within 3 Leading pharmaceutical and medical device companies rely on input from key opinion leaders—KOLs—to drive their critical projects forward. Now, at the dawn of a new era of virtual work, these organizations are freed from the timeframes and travel...
  • April 15, 2022
  • 0 Comment
Read More
Within 3 A US-based medical affairs team wanted to conduct new-hire MSL training focused on neurology topics
  • April 15, 2022
  • 0 Comment
Read More
Within 3 Life science companies invest significant resources in annual medical conferences and other in-person and hybrid events, and it’s important to maximize this investment through adequate preparation, meaningful participation, and actionable post-event activities.
  • April 15, 2022
  • 0 Comment
Read More
Within 3 The way pharmaceutical and medical device teams work has changed forever, prompting some experts to predict that everything from day-to-day interactions to how clinical trials are conducted will experience a transformation. Less business travel, more flexibility in where...
  • April 15, 2022
  • 0 Comment
Read More
Within 3 Medical affairs teams rely on insights to drive strategy and enable business decisions with far-reaching implications for their organizations, and for consumers who rely on life-changing treatments and devices. But the processes surrounding insight-gathering are varied, complex, and...
  • April 15, 2022
  • 0 Comment
Read More
Within 3 Life science organizations are facing a new world and unprecedented challenges. A global pandemic revealed vulnerabilities in processes from supply chain management to clinical trial recruitment and execution. As the global crisis progressed, pharmaceutical and medical device teams...
  • April 15, 2022
  • 0 Comment
Read More
Within 3 Life science and pharma companies have long looked to key opinion leaders (KOLs) for insights and advice. KOLs are highly respected and highly influential within their often large networks of peers. They are usually researchers, physicians, or other...
  • April 15, 2022
  • 0 Comment
Read More
UBC Pathway REMS Connect Overview – Improve prescriber experience, increase compliance, and reduce cost of REMS (Risk Evaluation & Mitigation Strategy) administration
  • April 14, 2022
  • 0 Comment
Read More
UBC BLUE BELL, Pa. and CARY, N.C., April 27, 2021 /PRNewswire/ — UBC, a late-stage research and patient-support services organization, and THREAD, a technology and service provide renabling DCTs, today announced UBC’s selection of THREAD to leverage decentralized approaches across...
  • March 15, 2022
  • 0 Comment
Read More